AUG 7, 2026 · PHASE 1 TRIAL
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease
ClinicalTrials.gov
This is a Phase 1 trial registration with no results yet posted; it describes a planned study of autologous B7-H3 CAR T cells in recurrent/refractory small cell lung cancer, currently not yet recruiting.
Reported
Planned enrollment40
PhasePhase 1
Primary outcome: Maximum tolerate…DLT assessment period day 0 through day 28